<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:22:04Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9466329" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9466329</identifier>
        <datestamp>2022-09-12</datestamp>
        <setSpec>bmcpedi</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMC Pediatr</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMC Pediatr</journal-id>
              <journal-title-group>
                <journal-title>BMC Pediatrics</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1471-2431</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9466329</article-id>
              <article-id pub-id-type="pmcid">PMC9466329</article-id>
              <article-id pub-id-type="pmc-uid">9466329</article-id>
              <article-id pub-id-type="pmid">36096775</article-id>
              <article-id pub-id-type="publisher-id">3562</article-id>
              <article-id pub-id-type="doi">10.1186/s12887-022-03562-1</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3319-5652</contrib-id>
                  <name>
                    <surname>Landier</surname>
                    <given-names>Wendy</given-names>
                  </name>
                  <address>
                    <email>wclandier@uabmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bhatia</surname>
                    <given-names>Smita</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Richman</surname>
                    <given-names>Joshua S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Campos Gonzalez</surname>
                    <given-names>Paula D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cherven</surname>
                    <given-names>Brooke</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chollette</surname>
                    <given-names>Veronica</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Aye</surname>
                    <given-names>Jamie</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Castellino</surname>
                    <given-names>Sharon M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gramatges</surname>
                    <given-names>Maria M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lindemulder</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Russell</surname>
                    <given-names>Thomas B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Turcotte</surname>
                    <given-names>Lucie M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Colditz</surname>
                    <given-names>Graham A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gilkey</surname>
                    <given-names>Melissa B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Klosky</surname>
                    <given-names>James L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000000106344187</institution-id><institution>Institute for Cancer Outcomes and Survivorship, </institution><institution>University of Alabama at Birmingham, </institution></institution-wrap>1600 7th Ave. South, Lowder 500, Birmingham, Alabama, 35233 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000000106344187</institution-id><institution>Department of Pediatrics, Division of Pediatric Hematology/Oncology, </institution><institution>University of Alabama at Birmingham, </institution></institution-wrap>1600 7th Ave. South, Lowder 512, Birmingham, Alabama, 35233 USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.428158.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0371 6071</institution-id><institution>Department of Pediatrics, </institution><institution>Emory University and Childrenâ€™s Healthcare of Atlanta, </institution></institution-wrap>2015 Uppergate Drive, ECC#412, Atlanta, GA 30322 USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.48336.3a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8075</institution-id><institution>Healthcare Systems and Interventions Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, </institution><institution>National Cancer Institute, </institution></institution-wrap>9609 Medical Center Dr., Room 3E344, MSC 9762, Rockville, MD 20850 USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.39382.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2160 926X</institution-id><institution>Department of Pediatrics, Division of Pediatric Hematology/Oncology, </institution><institution>Baylor College of Medicine, </institution></institution-wrap>1102 Bates St., Suite 1200, Houston, TX 77030 USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.5288.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 9758 5690</institution-id><institution>Department of Pediatrics, </institution><institution>Oregon Health &amp; Science University, </institution></institution-wrap>3181 SW Sam Jackson Park Road, Portland, Oregon, 97239 USA </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.241167.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2185 3318</institution-id><institution>Department of Pediatrics, </institution><institution>Wake Forest University, </institution></institution-wrap>Medical Center Boulevard, Winston-Salem, North Carolina 27157 USA </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.17635.36</institution-id><institution-id institution-id-type="ISNI">0000000419368657</institution-id><institution>Department of Pediatrics, </institution><institution>University of Minnesota, </institution></institution-wrap>D-557 Mayo Building, 420 Delaware Street SE, Minneapolis, MN 55455 USA </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution>Department of Surgery, </institution><institution>Washington University at St. Louis School of Medicine, </institution></institution-wrap>660 S. Euclid Ave, St. Louis, MO 63110 USA </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.410711.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 1720</institution-id><institution>Department of Health Behavior, Gillings School of Global Public Health, </institution><institution>University of North Carolina, </institution></institution-wrap>317 Rosenau Hall, CB #7440, 135 Dauer Drive, Chapel Hill, North Carolina 27599 USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>12</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>12</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <volume>22</volume>
              <elocation-id>541</elocation-id>
              <history>
                <date date-type="received">
                  <day>18</day>
                  <month>6</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2022</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Childhood cancer survivors are at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent infection with the human papillomavirus (HPV). HPV vaccination is effective in preventing the infections that lead to these cancers, but HPV vaccine uptake is low among young cancer survivors. Lack of a healthcare provider recommendation is the most common reason that cancer survivors fail to initiate the HPV vaccine. Strategies that are most successful in increasing HPV vaccine uptake in the general population focus on enhancing healthcare provider skills to effectively recommend the vaccine, and reducing barriers faced by the young people and their parents in receiving the vaccine. This study will evaluate the effectiveness and implementation of an evidence-based healthcare provider-focused intervention (HPV PROTECT) adapted for use in pediatric oncology clinics, to increase HPV vaccine uptake among cancer survivors 9 to 17Â years of age.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">This study uses a hybrid type 1 effectiveness-implementation approach. We will test the effectiveness of the HPV PROTECT intervention using a stepped-wedge cluster-randomized trial across a multi-state sample of pediatric oncology clinics. We will evaluate implementation (provider perspectives regarding intervention feasibility, acceptability and appropriateness in the pediatric oncology setting, provider fidelity to intervention components and change in provider HPV vaccine-related knowledge and practices [e.g., providing vaccine recommendations, identifying and reducing barriers to vaccination]) using a mixed methods approach.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par3">This multisite trial will address important gaps in knowledge relevant to the prevention of HPV-related malignancies in young cancer survivors by testing the effectiveness of an evidence-based provider-directed intervention, adapted for the pediatric oncology setting, to increase HPV vaccine initiation in young cancer survivors receiving care in pediatric oncology clinics, and by procuring information regarding intervention delivery to inform future implementation efforts. If proven effective, HPV PROTECT will be readily disseminable for testing in the larger pediatric oncology community to increase HPV vaccine uptake in cancer survivors, facilitating protection against HPV-related morbidities for this vulnerable population.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par4">ClinicalTrials.gov Identifier: NCT04469569, prospectively registered on July 14, 2020.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Human papillomavirus</kwd>
                <kwd>Vaccination rates</kwd>
                <kwd>Childhood cancer survivors</kwd>
                <kwd>Cluster-randomized trial</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>National Cancer Institute (US)</institution>
                  </funding-source>
                  <award-id>U01CA246567</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Landier</surname>
                      <given-names>Wendy</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© The Author(s) 2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>World Health Organization trial registration data set</title>
              <p id="Par23">
                <table-wrap id="Taba">
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <th align="left">Data category</th>
                        <th align="left">Information</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left">Primary registry and trial identifying number</td>
                        <td align="left">
                          <p>ClinicalTrials.gov</p>
                          <p>NCT04469569</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left">Date of registration in primary registry</td>
                        <td align="left">14 July 2020</td>
                      </tr>
                      <tr>
                        <td align="left">Secondary identifying numbers</td>
                        <td align="left">UAB IRB-300005305</td>
                      </tr>
                      <tr>
                        <td align="left">Source(s) of monetary or material support</td>
                        <td align="left">
                          <p>U.S. National Cancer Institute</p>
                          <p>U01CA246567 (PIs WL and JLK)</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left">Primary sponsor</td>
                        <td align="left">U.S. National Cancer Institute</td>
                      </tr>
                      <tr>
                        <td align="left">Secondary sponsor(s)</td>
                        <td align="left">University of Alabama at Birmingham</td>
                      </tr>
                      <tr>
                        <td align="left">Contact for public queries</td>
                        <td align="left">
                          <p>Wendy Landier, PhD</p>
                          <p>wclandier@uabmc.edu</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left">Contact for scientific queries</td>
                        <td align="left">
                          <p>Wendy Landier, PhD</p>
                          <p>wclandier@uabmc.edu</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left">Public title</td>
                        <td align="left">Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors</td>
                      </tr>
                      <tr>
                        <td align="left">Scientific title</td>
                        <td align="left">Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial</td>
                      </tr>
                      <tr>
                        <td align="left">Countries of recruitment</td>
                        <td align="left">United States</td>
                      </tr>
                      <tr>
                        <td align="left">Health condition(s) or problem(s) studied</td>
                        <td align="left">Prevention of HPV-related subsequent neoplasms in childhood cancer survivors</td>
                      </tr>
                      <tr>
                        <td align="left">Intervention(s)</td>
                        <td align="left">HPV PROTECT intervention vs. usual care</td>
                      </tr>
                      <tr>
                        <td align="left">Key inclusion and exclusion criteria</td>
                        <td align="left"><italic>Childhood cancer survivors:</italic> 9-17y of age;â€‰â‰¥â€‰1y following completion of cancer therapy; reside in state where targeted clinic is located; receiving follow-up care (in person or via telehealth) at participating site. <italic>Healthcare providers:</italic>â€‰â‰¥â€‰18y of age; provide care for childhood cancer survivors meeting inclusion criteria; licensed to order vaccines; willing to complete study surveys and/or interviews.</td>
                      </tr>
                      <tr>
                        <td align="left">Study type</td>
                        <td align="left">Interventional (clinical trial)</td>
                      </tr>
                      <tr>
                        <td align="left">Date of first enrolment</td>
                        <td align="left">1 Feb 2021</td>
                      </tr>
                      <tr>
                        <td align="left">Target sample size</td>
                        <td align="left">5196</td>
                      </tr>
                      <tr>
                        <td align="left">Recruitment status</td>
                        <td align="left">Recruiting</td>
                      </tr>
                      <tr>
                        <td align="left">Primary outcome(s)</td>
                        <td align="left">HPV vaccine initiation rates for childhood cancer survivors, age 9-17y andâ€‰â‰¥â€‰1y post-completion of cancer therapy</td>
                      </tr>
                      <tr>
                        <td align="left">Key secondary outcomes</td>
                        <td align="left">Healthcare provider perspectives regarding intervention feasibility, acceptability, appropriateness, and fidelity; change in healthcare provider HPV vaccine-related knowledge and practices following implementation of the HPV PROTECT intervention; HPV vaccine series completion rates among childhood cancer survivors; sustainability of HPV vaccine initiation rates.</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </p>
            </sec>
            <sec id="Sec2">
              <title>Background</title>
              <p id="Par24">Childhood cancer survivors are at high risk for developing new cancers (such as cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancer) caused by persistent infection with the human papillomavirus (HPV) [<xref ref-type="bibr" rid="CR1">1</xref>]. Compared with the age- and sex-matched general population, female and male cancer survivors have a 1.4- to 2.5-fold excess risk, respectively, of developing HPV-related malignancies [<xref ref-type="bibr" rid="CR2">2</xref>]. Fortunately, HPV-related malignancies are largely preventable due to availability of the nonavalent HPV vaccine [<xref ref-type="bibr" rid="CR3">3</xref>], which offers protection againstâ€‰~â€‰90% of oncogenic HPV subtypes [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. We have previously shown that uptake of the HPV vaccine is significantly lower in young cancer survivors compared with general population peers (22.0% <italic>vs</italic>. 42.5% in those age 13â€“17Â years), and that lack of healthcare provider recommendation is the strongest predictor of HPV vaccine non-initiation in cancer survivors [<xref ref-type="bibr" rid="CR6">6</xref>]. We have also shown that the HPV vaccine is safe in young cancer survivors, and that immunogenicity of the 3-dose HPV vaccine series is similar to that seen in the general population [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
              <p id="Par25">Young people with chronic health conditions, including cancer survivors, often identify their subspecialty provider (i.e., oncologist) as their main healthcare provider [<xref ref-type="bibr" rid="CR8">8</xref>], have greater confidence in healthcare recommendations made by their oncology providers as compared with primary care providers (PCPs) [<xref ref-type="bibr" rid="CR9">9</xref>], and may forgo routine primary care services. This may result in receipt of fragmented medical care and unmet healthcare needs, including under-vaccination [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Targeting an intervention to pediatric oncology practices provides an opportunity to address low HPV vaccine uptake in childhood cancer survivors, particularly since return of young people to primary care settings for receipt of preventive care has been identified as a barrier to HPV vaccine initiation in the general [<xref ref-type="bibr" rid="CR11">11</xref>] and subspecialty [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>] populations, and survivors regularly return to pediatric oncology clinics for disease-surveillance and survivorship-directed care [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p>
              <p id="Par26">Strategies that are most successful in increasing HPV vaccine uptake in the general population focus on enhancing the skills that healthcare providers need to effectively recommend the vaccine, and reducing barriers faced by young people and their parents to receiving the vaccine [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Successful interventions to improve HPV vaccine uptake in the pediatric/adolescent general population have included healthcare provider communication training [<xref ref-type="bibr" rid="CR17">17</xref>â€“<xref ref-type="bibr" rid="CR19">19</xref>], provider assessment and feedback [<xref ref-type="bibr" rid="CR20">20</xref>â€“<xref ref-type="bibr" rid="CR24">24</xref>], and tools/resources to engage providers in implementation of practice-level changes that positively impact adolescent HPV vaccine uptake [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. These existing evidence-based interventions offer a strong foundation for working with providers to improve HPV vaccine uptake, with the caveat that they were developed for use in primary care [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>â€“<xref ref-type="bibr" rid="CR31">31</xref>]. Adaptation is needed to support their implementation in the oncology settings that serve young cancer survivors.</p>
              <p id="Par27">In this study, we will test the effectiveness of a package of evidence-based intervention materials [<xref ref-type="bibr" rid="CR17">17</xref>â€“<xref ref-type="bibr" rid="CR26">26</xref>], adapted for use by pediatric oncology providers (HPV PROTECT: Healthcare ProVider intervention PROmoting HPV vaccination among TEens after Cancer Treatment), in improving HPV vaccination rates among young cancer survivors, age 9 to 17, and evaluate its implementation in the context of cancer survivorship care.</p>
              <p id="Par28">The HPV PROTECT intervention is comprised of three components i) <italic>Provider Communication Training</italic>, designed to increase the quality of provider recommendations as well as the proportion of patients who receive the high quality recommendations for the HPV vaccine [<xref ref-type="bibr" rid="CR32">32</xref>]; ii) <italic>Assessment and Peer Feedback/Coaching</italic>, which delivers current vaccination rates and clinic goals, as well as highlights techniques to meet those goals [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], and iii) <italic>Provider Toolkit</italic>, which provides practice-focused resources to promote HPV vaccination [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Thus, HPV PROTECT is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>HPV PROTECT intervention</p></caption><graphic xlink:href="12887_2022_3562_Fig1_HTML" id="MO1"/></fig></p>
              <p id="Par29">We will monitor vaccination rates at participating sites throughout the study using state vaccine registries. State vaccine registries (also known as Immunization Information Systems) are confidential, population-based, electronic data repositories across the United States (U.S.) for storage of vaccination information from multiple sources (e.g., health departments, hospitals, clinics, pharmacies and private practices) [<xref ref-type="bibr" rid="CR33">33</xref>]. The registries are coordinated by the Centers for Disease Control, which maintains Functional Standards, Core Data Elements, and Technical Guidance for these systems within the U.S. [<xref ref-type="bibr" rid="CR33">33</xref>]. Vaccine registry data have been used in numerous studies to assess outcomes of interventions designed to increase immunization uptake [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR34">34</xref>â€“<xref ref-type="bibr" rid="CR37">37</xref>] and have been shown to be reliable when compared with medical records and parental report [<xref ref-type="bibr" rid="CR38">38</xref>]. Thus, state vaccine registries are a robust source for assessing vaccine uptake, regardless of where survivors receive their vaccinations within the state [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p>
              <p id="Par30">This study will use a hybrid type 1 effectiveness-implementation approach [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Effectiveness of the HPV PROTECT intervention will be evaluated in a cluster-randomized, stepped-wedge trial [<xref ref-type="bibr" rid="CR43">43</xref>] over 4Â years, with a multi-state sample of pediatric oncology clinics that provide care to cancer survivors within the targeted age (9â€“17Â years) and time frame (â‰¥â€‰1Â year off-therapy) for vaccination [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The study will simultaneously evaluate implementation outcomes (provider perspectives regarding feasibility, acceptability and appropriateness of HPV PROTECT in pediatric oncology clinics, intervention fidelity, and change in healthcare provider HPV vaccine-related knowledge and practices) to inform future implementation strategies.</p>
            </sec>
            <sec id="Sec3">
              <title>Objectives</title>
              <sec id="Sec4">
                <title>Primary objective</title>
                <p id="Par31">Among childhood cancer survivors 9â€“17Â years of age andâ€‰â‰¥â€‰1Â year post-completion of cancer therapy (targeted age/time frame for vaccination) who are returning for follow-up care (in-person or via telehealth) across six geographically-diverse pediatric oncology clinics, conduct a cluster-randomized, stepped-wedge trial to evaluate the effectiveness of HPV PROTECT in improving HPV vaccine initiation rates one year post-intervention. We hypothesize that implementation of HPV PROTECT will significantly increase HPV vaccine initiation rates in survivors of childhood cancer.</p>
              </sec>
              <sec id="Sec5">
                <title>Secondary objectives</title>
                <p id="Par32">Ascertain healthcare provider perspectives regarding feasibility, acceptability and appropriateness of HPV PROTECT in the pediatric oncology setting; assess intervention fidelity; and estimate change in healthcare provider HPV vaccine-related knowledge and practices.</p>
              </sec>
              <sec id="Sec6">
                <title>Exploratory objectives</title>
                <p id="Par33">Estimate the effect of HPV PROTECT on: i) HPV vaccine series completion; and ii) ongoing improvement in HPV vaccine initiation rates in the years subsequent to HPV PROTECT implementation (sustainability).</p>
              </sec>
            </sec>
            <sec id="Sec7">
              <title>Implementation framework</title>
              <p id="Par34">This study will employ the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) implementation framework [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] to evaluate implementation outcomes (i.e., process evaluation) [<xref ref-type="bibr" rid="CR48">48</xref>]. Data for this evaluation will be collected simultaneously with the effectiveness trial to inform future implementation efforts. A mixed-methods approach (surveys and qualitative interviews) will be used to conduct the outcomes evaluation, with questions and tools/methods guided by the RE-AIM framework.</p>
            </sec>
            <sec id="Sec8">
              <title>Methods</title>
              <sec id="Sec9">
                <title>Ethics approval</title>
                <p id="Par35">The study described here was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board (IRB-300005305), with UAB serving as the single IRB (sIRB) of record. In accordance with the SMART (Streamlined, Multisite, Accelerated Resources for Trials) IRB reliance model, participating sites ceded review to the UAB IRB as the Reviewing IRB under the Master Common Reciprocal IRB Authorization Agreement.</p>
              </sec>
              <sec id="Sec10">
                <title>Study design, setting, and population</title>
                <p id="Par36">A hybrid type 1 effectiveness-implementation design will be used to test the effectiveness of the HPV PROTECT healthcare provider-directed intervention in improving HPV vaccine uptake in childhood cancer survivors, and to evaluate implementation outcomes (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>)<italic>.</italic> This study will be conducted at six participating sites (The University of Alabama at Birmingham/Childrenâ€™s of Alabama, Emory University/Childrenâ€™s Healthcare of Atlanta, Baylor College of Medicine/Texas Childrenâ€™s Hospital, Oregon Health &amp; Science University/Doernbecher Childrenâ€™s Hospital, Atrium Health Wake Forest Baptist, and the University of Minnesota/M Health Fairview Masonic Childrenâ€™s Hospital). Each of these sites have active pediatric oncology outpatient clinics that provide ongoing care for young cancer survivors 9â€“17Â years of age and at least 1Â year off-therapy, and each clinic has existing access to their state vaccine registry via their electronic medical record (EMR) system. Sites were chosen to be representative of pediatric oncology practices of varying characteristics including varied geographic location, size, and patient populations, and were especially enriched for sites serving populations in areas of lowest HPV vaccine uptake (i.e., U.S. southern states) [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. None of these sites have a standardized (quality improvement) program in place to address HPV vaccine initiation in cancer survivors. Each site has an identified Intervention Champion, who will be responsible for all aspects of the study at their site, including overseeing data collection, engaging and training providers in the targeted pediatric oncology clinics, identifying context-specific resources, assuring availability and context-appropriateness of intervention resources, providing ongoing group peer feedback/coaching sessions to providers, overseeing interface with clinic support staff in carrying out all aspects of the intervention, and assuring intervention fidelity. Each participating site has agreed to operationalize HPV PROTECT as a quality improvement (QI) initiative; therefore, all providers caring for cancer survivors will be expected to complete the training sessions, and will be given access to all intervention components at the time of intervention implementation. Healthcare providers at the participating sites will be invited, but not required, to participate in the research aspects of the project.<fig id="Fig2"><label>Fig. 2</label><caption><p>Hybrid type 1 effectiveness-implementation trial design</p></caption><graphic xlink:href="12887_2022_3562_Fig2_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="Sec11">
                <title>HPV PROTECT intervention components</title>
                <sec id="Sec12">
                  <title>Provider communication training</title>
                  <p id="Par37">This training session, presented to clinicians at each site by the Intervention Champion, is based on the Announcement Approach Training framework [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Content of the program is tailored to the pediatric oncology provider caring for young cancer survivors, and includes survivor-specific information, such as timing of vaccination post-therapy, and number of doses needed to complete the vaccine series [<xref ref-type="bibr" rid="CR7">7</xref>]. Thus, this training is designed to increase provider knowledge of survivor-specific HPV vaccine issues and to enhance provider skills in recommending HPV vaccine to young cancer survivors and their parents.</p>
                </sec>
                <sec id="Sec13">
                  <title>Assessment and peer feedback/coaching</title>
                  <p id="Par38">This training session, presented to clinicians at each site by the Intervention Champion, includes review of specific evidence related to risk of HPV-related cancers in childhood cancer survivors, the low vaccine uptake among survivors, and the specific HPV vaccination rates among 9â€“17-year-old cancer survivors at the site (using Vaccine Report Card data). The Intervention Champion will also describe the HPV PROTECT intervention components and resources, identify the siteâ€™s goal for improving HPV vaccine initiation rates for survivors, and highlight the techniques and tools that will be employed toward meeting the goal [<xref ref-type="bibr" rid="CR20">20</xref>â€“<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p>
                </sec>
                <sec id="Sec14">
                  <title>Provider toolkit</title>
                  <p id="Par39">This toolkit will be introduced by the Intervention Champion and made available to clinicians at each site during the Intervention Year. The Provider Toolkit includes practice-focused resources designed to facilitate HPV vaccine uptake in the pediatric oncology setting [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], as follows: <italic>i) Vaccine Action Plan</italic> for providers to complete with parents, tailored to local context. For example, the Vaccine Action Plan will include details regarding where the survivor can initiate and/or complete the vaccine series, if not feasible in the pediatric oncology setting (e.g., PCP office, health department, pharmacy) based on local context and site-specific practices; <italic>ii) Provider Recommendation Note Cards</italic>, which summarize key messages for recommending the HPV vaccine to survivors, as presented in the communication training session; <italic>iii) Survivor Vaccine Fact Sheets</italic>, which highlight pediatric oncology-specific information regarding the HPV vaccine for survivors; <italic>iv) Standardized templates for oncologist-PCP communication</italic>, regarding the vaccination plan; <italic>v) Standardized templates for oncologist-parent communication</italic> regarding the agreed-upon plan for vaccination, for inclusion in clinic discharge paperwork; <italic>vi) EMR Documentation Template</italic>, for documenting discussion of the HPV vaccine recommendation and plan for vaccine receipt in the EMR; and vii) <italic>HPV PROTECT Intervention Website</italic>, which provides access to intervention resources and video-recordings of training sessions for providers at participating sites. All HPV PROTECT components are designed to be accessible via this web-based platform. All participating study sites will have access to the HPV PROTECT website, with controlled release concurrent with the intervention year.</p>
                </sec>
              </sec>
              <sec id="Sec15">
                <title>Adaptation of the intervention to local context</title>
                <p id="Par40">Intervention Champions will be given the opportunity to adapt components of the Provider Toolkit (e.g., Vaccine Action Plan; Recommendation Videos), in order to add salient information that may be necessary for survivors to procure the vaccine locally, as well as to adapt training videos to feature local influential providers.</p>
              </sec>
              <sec id="Sec16">
                <title>Intervention fidelity</title>
                <p id="Par41">To assure intervention fidelity, all components of the intervention will be standardized and manualized prior to delivery. The site Intervention Champions will undergo intensive intervention-specific training (including a 2-day intensive training group program followed by individual meetings) led by the study PIs and co-investigators with intervention-related expertise, beginning two to three months prior to intervention implementation at their sites. This train-the-trainer approach includes review of all aspects of the intervention, use of the intervention manual, training in skill sets relevant to leading the intervention and supporting providers at their sites, and assistance in adapting intervention materials to local context. The site Intervention Champions will be responsible for monitoring all aspects of fidelity at their sites and for completion of a fidelity checklist. Toolkit resources will be tailored to site-specific local context as specified in the intervention manual; however, all training sessions for healthcare providers, including those adapted for local context, will remain scripted, regardless of the individual delivering the messaging. Thus, training sessions delivered by the site Intervention Champions, will incorporate standardized scripts and presentation materials, and will be observed by the study Principal Investigators (PIs) for fidelity. Intervention Champions will monitor provider participation in intervention training sessions and ongoing use of intervention components (including Toolkit resources) at their sites, and will track participation in peer feedback meetings. Site Intervention Champions and study PIs will meet at least quarterly to address any issues or challenges that may arise.</p>
              </sec>
              <sec id="Sec17">
                <title>Participants</title>
                <sec id="Sec18">
                  <title>Healthcare providers</title>
                  <p id="Par42">Healthcare providers are the main target for this implementation trial, and the provider-directed intervention occurs at the clinic level; thus, the research component of the trial focuses on the providers. Eligible providers will be invited to participate in the research study in order to assess their knowledge and current practices related to the HPV vaccine in young cancer survivors, and to understand provider perspectives regarding the feasibility, acceptability and appropriateness of the HPV PROTECT intervention components, and provider adherence (fidelity) to each of the intervention components.</p>
                </sec>
                <sec id="Sec19">
                  <title>Childhood cancer survivors</title>
                  <p id="Par43">The population of interest for measurement of HPV vaccine initiation and completion rates is defined as: Childhood cancer survivors, who are 9 to 17Â years of age and at least 1-year following completion of cancer therapy, and are returning to one of the targeted pediatric oncology clinics for follow-up care.</p>
                </sec>
              </sec>
              <sec id="Sec20">
                <title>Recruitment</title>
                <sec id="Sec21">
                  <title>Healthcare providers</title>
                  <p id="Par44">Potential participants for this study will be identified using rosters of eligible healthcare providers, and their associated email addresses, at participating sites (compiled by the site Intervention Champions). Each site Intervention Champion will send all eligible healthcare providers at their site an email introducing the study coordinating center and describing study procedures, including risks and benefits of participation. The study coordinating center will then send each eligible healthcare provider an invitation to participate in the study.</p>
                </sec>
                <sec id="Sec22">
                  <title>Childhood cancer survivors</title>
                  <p id="Par45">Childhood cancer survivor vaccine initiation and completion rates will be measured as part of each siteâ€™s QI initiative to increase HPV vaccination rates. No patient/parent recruitment will be conducted by the sites, since patients/parents will be only indirectly involved in the research through the calculation of clinic-level vaccination rates, and a full Health Information Portability and Accountability (HIPAA) waiver is in place. All patient-level data collected for this study will be completely de-identified (removal of the 18 protected health information [PHI] identifiers), prior to submission to the study coordinating center.</p>
                </sec>
              </sec>
              <sec id="Sec23">
                <title>Inclusion and exclusion criteria</title>
                <sec id="Sec24">
                  <title>Healthcare providers</title>
                  <p id="Par46"><italic>Inclusion:</italic> Healthcare providers (physicians, advanced practice providers) in the targeted pediatric oncology clinics at the participating sites: i) caring for childhood cancer survivors; ii) licensed to order vaccines; iii) willing to complete surveys and/or interviews. <italic>Exclusion:</italic> Meets eligibility criteria but unwilling to provide informed consent for study participation.</p>
                </sec>
                <sec id="Sec25">
                  <title>Childhood cancer survivors</title>
                  <p id="Par47"><italic>Inclusion:</italic> Childhood cancer survivors who are 9â€“17Â years of age,â€‰â‰¥â€‰1Â year following completion of cancer therapy, receive follow-up care (in person or via telehealth) in a targeted pediatric oncology clinic at a participating site, and reside in the state where the clinic is located. <italic>Exclusion:</italic> State vaccine registry data not available for the survivor.</p>
                </sec>
              </sec>
              <sec id="Sec26">
                <title>Informed consent</title>
                <sec id="Sec27">
                  <title>Healthcare providers</title>
                  <p id="Par48">Healthcare providers who provide care to patients in the targeted population will receive a study email from the coordinating center with an information sheet, along with a link to the online survey. The IRB has authorized waiver of consent documentation; thus, completion of the survey will imply consent. An item on the survey will ask the healthcare provider if they wish to participate in study interviews. Those indicating interest in interview participation will be contacted by the study Clinical Research Assistant (CRA) at the study coordinating center via email or telephone. Verbal consent will be obtained prior to interview initiation.</p>
                </sec>
                <sec id="Sec28">
                  <title>Childhood cancer survivors</title>
                  <p id="Par49">There will be no interaction between the study team and cancer survivors. Study involvement includes abstraction of existing clinical information only.</p>
                </sec>
              </sec>
              <sec id="Sec29">
                <title>Approach</title>
                <sec id="Sec30">
                  <title>Effectiveness trial</title>
                  <p id="Par50">The HPV PROTECT intervention will be implemented as standard of care (quality improvement), and will be evaluated across the six participating sites using a cluster-randomized stepped-wedge design. During the first year of the trial, all six participating sites will be assigned to the baseline (control) condition in which they will proceed with usual care and measure HPV vaccination rates of the targeted population (cancer survivors 9â€“17Â years of age andâ€‰â‰¥â€‰1Â year following completion of therapy) using state vaccine registry data accessible via EMRs. In Year 2, three of the sites will implement <italic>HPV PROTECT</italic> while the remaining three sites will continue with usual care. In Year 3, the remaining three sites will implement <italic>HPV PROTECT,</italic> and sustainability of the intervention will be evaluated for the three sites that implemented <italic>HPV PROTECT</italic> in Year 2. In Year 4, sustainability (i.e., ongoing improvement in vaccine initiation rates) of the <italic>HPV PROTECT</italic> intervention will be evaluated across all six sites. Measurement of HPV vaccination rates using state vaccine registry data accessible via EMRs will continue across the entire 4-year period of the trial.</p>
                </sec>
                <sec id="Sec31">
                  <title>Implementation trial</title>
                  <p id="Par51">To inform future dissemination of the intervention, we will use a mixed methods approach to estimate change in healthcare provider HPV vaccine-related knowledge and practice; evaluate healthcare provider perspectives regarding intervention feasibility, acceptability, and appropriateness in the pediatric oncology setting; and evaluate provider adherence (fidelity) to intervention components.</p>
                  <p id="Par52">All of the targeted pediatric oncology healthcare providers at each clinic will be invited to complete electronically-administered surveys, yearly for four years, via <italic>Research Electronic Data Capture (REDCapÂ®)</italic> [<xref ref-type="bibr" rid="CR51">51</xref>], a secure password-protected, web-based research database, regarding their HPV vaccine-related knowledge, current HPV vaccine-related practices (e.g., provision of vaccine recommendations to parents/patients), their evaluation of the HPV PROTECT intervention components, and their sociodemographic information (e.g., age, sex, education, role, years of experience). Healthcare providers who complete surveys will be asked to indicate if they would like to participate in qualitative interviews in the survey year during which the participantâ€™s site is implementing the HPV PROTECT intervention. Healthcare providers who indicate interest in interview participation will be invited to participate in telephone or secure web-based interviews regarding feasibility and acceptability of the intervention components and barriers/facilitators to implementation of the intervention. Interviews will be recorded and transcribed by the coordinating center CRA. Personal identifiers will be removed from the data by the CRA following data collection. Results will be reported in aggregate without personal identifiers.</p>
                </sec>
              </sec>
              <sec id="Sec32">
                <title>Randomization</title>
                <p id="Par53">In this stepped-wedge cluster-randomized design, randomization will occur at the site level, with three sites randomized to begin the intervention in Year 2, and three sites randomized to begin the intervention in Year 3 (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>). There is no difference in the intervention between the two groups other than the intervention start date. The studyâ€™s stepped-wedge design incorporates a control period for all participating sites during Year 1, allowing for collection of baseline vaccination rates, thus avoiding historical comparisons. Before the beginning of Year 2, sites will be randomized according to the stepped-wedge design. The sites assigned to the control condition in Year 2 (sites A, B, C) will be assigned to the intervention in Year 3, and the Year 2 intervention sites (sites D, E, F) will be moved to the post-intervention (sustainability) condition for Year 3. All sites will be assigned to the post-intervention (sustainability) condition for Year 4. The stepped wedge design will allow comparison of the primary outcome (HPV vaccine initiation rate; i.e., proportion of survivors in targeted population who have receivedâ€‰â‰¥â€‰1 HPV vaccine dose, as of the last day of each study year) across groups (control vs. intervention), while allowing each site to serve as its own pre-intervention control, and using the control observations in Years 1 (all sites) and 2 (sites A, B, C) to estimate secular trends. Sustainability will be assessed in the post-implementation period, i.e., in Years 3 (sites D, E, F) and 4 (all sites) (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Stepped-wedge cluster-randomized trial design</p></caption><graphic xlink:href="12887_2022_3562_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Study schema</p></caption><graphic xlink:href="12887_2022_3562_Fig4_HTML" id="MO4"/></fig></p>
              </sec>
              <sec id="Sec33">
                <title>Measures</title>
                <sec id="Sec34">
                  <title>Healthcare provider data</title>
                  <p id="Par54">Participating healthcare providers will complete the following:</p>
                  <p id="Par55"><italic>Healthcare Provider Electronic Survey</italic>. The healthcare provider survey will be completed electronically via <italic>REDCapÂ®</italic> yearly for 4Â years in Years 1â€“4; estimated completion time is 15Â min per year. The survey will ascertain the following data: Sociodemographics (age, sex, race/ethnicity, education); Clinical characteristics (provider license type [MD, NP, PA]; role [attending, staff, trainee], years of experience in current role, average number of survivors seen per week); provider HPV vaccine-related knowledge/practices (knowledge regarding HPV vaccine, familiarity with strategies to increase vaccine uptake, recall [or prior knowledge] of key messages in the training program, current practices related to the HPV vaccine (e.g., method used to assess survivor vaccination status, frequency and quality of recommendation for HPV vaccine, strategies used to promote HPV vaccination); and intervention evaluation (objective rating of feasibility, acceptability, appropriateness of the intervention in the pediatric oncology setting and provider fidelity to intervention components [e.g., vaccine recommendations, educational materials]).</p>
                  <p id="Par56"><italic>Healthcare Provider Qualitative Interview.</italic> Semi-structured qualitative interviews will be conducted with those healthcare providers who opt-in to this portion of the study. The interviews will occur once, during the year that the healthcare providerâ€™s site initiates the intervention; estimated interview duration is 30Â min. Providers will be asked about their perceptions of the feasibility (perceived potential for success), acceptability (perceived need), and appropriateness (perceived fit) of the intervention to the pediatric oncology setting, and their adherence (fidelity) to intervention components (e.g., delivery of recommendations, developing and communicating vaccine action plans to parents and PCPs). Interviews will be conducted during the second half of Year 2 (sites D, E, F) and Year 3 (Sites A, B, C) via telephone or secure web-based platform by an interviewer from the coordinating center trained in qualitative interview techniques. An Interview Guide will be used and interviews will be recorded and transcribed verbatim.</p>
                </sec>
                <sec id="Sec35">
                  <title>Patient-level data</title>
                  <p id="Par57">The intervention occurs at the clinic level, and medical record and vaccine registry data for the cancer survivor population will be accessed by the site CRA under a HIPAA waiver as part of each siteâ€™s QI initiative. The site CRA will abstract the following data elements from the medical record for each survivor added to the study roster: Diagnosis category (leukemia, lymphoma, solid tumor, central nervous system [CNS] tumor); age at diagnosis, time from diagnosis, and time off-therapy at cohort entry; history of hematopoietic cell transplant (yes/no; if yes: type, number, age); history of Chimeric Antigen Receptor (CAR)-T cell therapy (yes/no: If yes: number, age); sex; and race/ethnicity. The CRA will abstract the following additional visit-specific data elements from the survivorâ€™s medical record for the initial clinic visit and for each subsequent clinic visit occurring during the study period: Age at visit, study year and week of visit, provider type (physician, advanced practice provider), study identification number of healthcare provider(s) providing care at clinic visit, visit type (in-person, telehealth), and insurance type.</p>
                  <p id="Par58">Upon adding each survivor to the study roster, the CRA will access the state vaccine registry and abstract all HPV vaccine dose(s) and associated date(s) of administration occurring prior to the date of the survivorâ€™s cohort entry visit. At least yearly throughout the data collection period (Years 1â€“4), the CRA will access the state vaccine registry and abstract any additional HPV vaccine dose(s) and associated date(s) of administration occurring since the most recent data abstraction. Additionally, dose(s) and date(s) of additional vaccines recommended for adolescents (i.e., meningococcal, Tdap, influenza and COVID-19), will be abstracted by the CRAs at the same timepoints, for use as co-variates in the analysis, as it is important to understand whether uptake of the HPV vaccine differs from uptake of the other recommended adolescent vaccines [<xref ref-type="bibr" rid="CR52">52</xref>]. All data will be completely de-identified prior to submission to the study coordinating center; survivors with visits in more than one year will be linked so that multiple observations per survivor can be addressed in the analysis. Coded roster data (with no elements of personal health information [PHI]) will be submitted weekly by participating sites to the study coordinating center via the studyâ€™s REDCapÂ® study database. Data quality will be monitored in real-time by the site CRAs for each individual site and by the CRA at the study coordinating center for the overall study, using the study Standardized Operating Procedures, which include detailed instructions for data collection, verification, and cleaning. Additionally, range checks for key variables, and warnings to prevent missing data,Â are built into the REDCapÂ® study database.</p>
                </sec>
              </sec>
              <sec id="Sec36">
                <title>Outcomes</title>
                <sec id="Sec37">
                  <title>Primary outcome</title>
                  <p id="Par59">Change in survivor HPV vaccine initiation rates one year following intervention implementation, measured using state vaccine registry data accessed via the EMR at each participating site as part of the QI project associated with this research. The primary outcome will be measured as of the final day of the intervention year (Year 2 for sites DEF, Year 3 for sites ABC).</p>
                </sec>
                <sec id="Sec38">
                  <title>Secondary outcomes</title>
                  <p id="Par60">Healthcare provider knowledge and current practices related to the HPV vaccine, measured by survey (yearly in Years 1â€“4). Provider perspectives regarding feasibility/acceptability and appropriateness of the intervention in the pediatric oncology setting, and provider adherence (fidelity) to intervention components, measured by survey (yearly in Years 1â€“4), and interview (once during intervention year [Year 2 or Year 3]).</p>
                </sec>
                <sec id="Sec39">
                  <title>Exploratory outcomes</title>
                  <p id="Par61">Change in survivor HPV vaccine series completion rates, and ongoing HPV vaccine initiation rates in years subsequent to implementation of the intervention (sustainability), measured using state vaccine registry data accessed via the EMR at each participating site as part of the QI project associated with this research. The exploratory outcomes will be measured as of the final day of each relevant study year.</p>
                </sec>
              </sec>
              <sec id="Sec40">
                <title>Analytic plan</title>
                <sec id="Sec41">
                  <title>Effectiveness trial</title>
                  <p id="Par62">Unless otherwise noted, all statistical tests will be two-sided. The main hypothesis of the interventionâ€™s effect will be tested using a mixed effects logistic regression model including a random intercept for each site. The base model for HPV vaccine initiation for participant <italic>i</italic> at site<italic> j</italic> during year<italic> y</italic> without covariates will be:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{log}\left({Odds}_{initiation,i,j,y}\right)={\beta }_{0}+{\beta }_{1}\bullet {year}_{j,y}+{\beta }_{2}\bullet {x}_{intervention,j,y}+{b}_{j}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mi mathvariant="normal">log</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mrow><mml:mi mathvariant="italic">Odds</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>âˆ™</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">year</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>âˆ™</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math><graphic xlink:href="12887_2022_3562_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p>
                  <p id="Par63">where <inline-formula id="IEq1"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${year}_{i,j}$$\end{document}</tex-math><mml:math id="M4"><mml:msub><mml:mrow><mml:mi mathvariant="italic">year</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq1.gif"/></alternatives></inline-formula> indicates the study-year of the visit, and <inline-formula id="IEq2"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${x}_{intervention,j,y}$$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq2.gif"/></alternatives></inline-formula> equals 0 if site <italic>j</italic> has not been exposed to the intervention by <inline-formula id="IEq3"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${year}_{j,y}$$\end{document}</tex-math><mml:math id="M8"><mml:msub><mml:mrow><mml:mi mathvariant="italic">year</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq3.gif"/></alternatives></inline-formula>, and equals 1 if it has, and <inline-formula id="IEq4"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${b}_{j}$$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mi>b</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq4.gif"/></alternatives></inline-formula> is the random intercept for site <italic>j</italic>. The primary hypothesis will be tested by the significance of the coefficient <inline-formula id="IEq5"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{2}$$\end{document}</tex-math><mml:math id="M12"><mml:msub><mml:mi>Î²</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq5.gif"/></alternatives></inline-formula> in the model, which will capture the initial year of active intervention. Exploratory aims include testing whether the intervention results in increased rates of series completion and whether there is a sustained intervention effect in increasing HPV vaccine initiation. The analysis for series completion will parallel the analysis for initiation, with the exception that the analytic cohort for each year will be limited to those who had not completed the series prior to their index clinic visit for that year. Sustained effects will be tested using a similar model augmented by specific coefficients for duration of time in the intervention arm:<disp-formula id="Equb"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{log}\left({Odds}_{initiation,i,j,y}\right)={\beta }_{0}+{\beta }_{1}\bullet {year}_{j,y}+{\beta }_{2}\bullet {x}_{intevention,j,y}+{\beta }_{3}\bullet {x}_{2int,j,y}+{\beta }_{4}\bullet {x}_{3int,j,y}+{b}_{j}$$\end{document}</tex-math><mml:math id="M14" display="block"><mml:mrow><mml:mi mathvariant="normal">log</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mrow><mml:mi mathvariant="italic">Odds</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>âˆ™</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">year</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>âˆ™</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>âˆ™</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:mo>âˆ™</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math><graphic xlink:href="12887_2022_3562_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p>
                  <p id="Par64">In this model, <inline-formula id="IEq6"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{1}$$\end{document}</tex-math><mml:math id="M16"><mml:msub><mml:mi>Î²</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq6.gif"/></alternatives></inline-formula> will continue to account for a constant secular trend, while <inline-formula id="IEq7"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{3}$$\end{document}</tex-math><mml:math id="M18"><mml:msub><mml:mi>Î²</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq7.gif"/></alternatives></inline-formula> will allow for an additional effect in the 2<sup>nd</sup> year of intervention and <inline-formula id="IEq8"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{4}$$\end{document}</tex-math><mml:math id="M20"><mml:msub><mml:mi>Î²</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq8.gif"/></alternatives></inline-formula> will similarly allow for an additional incremental effect in the third year. Thus, the log odds of initiation for a participant at site <italic>j</italic> in year 4 for a site in the third year of intervention will be estimated as <inline-formula id="IEq9"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{0}+{\beta }_{1}\bullet 4+{\beta }_{2}+{\beta }_{3}+{\beta }_{4}$$\end{document}</tex-math><mml:math id="M22"><mml:mrow><mml:msub><mml:mi>Î²</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>âˆ™</mml:mo><mml:mn>4</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Î²</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq9.gif"/></alternatives></inline-formula> + <inline-formula id="IEq10"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${b}_{j}$$\end{document}</tex-math><mml:math id="M24"><mml:msub><mml:mi>b</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq10.gif"/></alternatives></inline-formula>. While hypothesis testing will be included in the exploratory aims, the focus will be on reporting estimated rates of outcomes and intervention effects with confidence intervals. For each outcome, secondary analyses will include patient age at visit, sex, insurance type, and race/ethnicity as covariates to improve the precision of estimates and provide an estimated standardized prevalence. We will also evaluate the impact of clinic level factors on vaccination initiation rates (e.g., clinic volume, provider characteristics, practice size, geographic location, and baseline initiation rates) as fixed effects. We will also report the HPV vaccine initiation rate among survivors who were vaccine-naÃ¯ve at cohort entry (i.e., incidence of vaccine initiation). Last, we will perform subgroup analyses stratified by relevant biological variables (i.e., age at visit, sex, and race/ethnicity groups). For survivors who completeâ€‰&gt;â€‰1 clinic visit/study year, the number and timing of subsequent clinic visits during the study period will be included as covariates in secondary analyses. Patients who develop a relapse or subsequent malignancy requiring active cancer treatment at any time during the study period will be removed from the data set as of the date of diagnosis of the relapse or subsequent malignancy. Parallel analyses will further consider providers as random effects within sites, adding a random intercept for each provider. Given the potential complexity of correlation structures and nesting, the main hypothesis tests will also be reported using permutation testing. As an example, for permutation testing the main effect based on coefficient <inline-formula id="IEq11"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{2}$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mi>Î²</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq11.gif"/></alternatives></inline-formula>, for multiple (&gt;â€‰1000) iterations, participants will be randomly assigned to sites and the models fit to develop an empirical distribution for estimates of <inline-formula id="IEq12"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{2}$$\end{document}</tex-math><mml:math id="M28"><mml:msub><mml:mi>Î²</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq12.gif"/></alternatives></inline-formula> under the null hypothesis of not different. The p-value of <inline-formula id="IEq13"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\beta }_{2}$$\end{document}</tex-math><mml:math id="M30"><mml:msub><mml:mi>Î²</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:math><inline-graphic xlink:href="12887_2022_3562_Article_IEq13.gif"/></alternatives></inline-formula> (with genuine assignments) will be estimated from distribution of coefficients estimated from the permutations.</p>
                  <p id="Par65"><italic>Sample Size and Power.</italic> Based on a combination of our prior work [<xref ref-type="bibr" rid="CR6">6</xref>], secular trends since publishing that work, and general population data regarding state-specific vaccination rates [<xref ref-type="bibr" rid="CR53">53</xref>], pre-intervention prevalence rates of vaccine-initiated patients at the 6 sites are estimated to be 0.404, 0.496, 0.462, 0.473, 0.415, and 0.488, for an average prevalence rate of 0.456, with a stable baseline incidence initiation of 0.025 (or 2.5 absolute percentage points) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. For evaluating the intervention, we expect to have approximately 1273 patients with clinic visits per year with site-specific numbers estimated as 227, 215, 135, 104, 403, and 189. Power was estimated using simulations making conservative assumptions about the number of available appointments, and rates of increase. From simulations, we haveâ€‰&gt;â€‰80% power to detect increased rates of initiation resulting in average prevalence after year 2 (1<sup>st</sup> year of intervention) of 48.2% for the control practices vs. 57.0% for the intervention practices, an absolute difference of 8.7%, which is less than the 10% difference we expect to observe. In terms of the logistic regression model, this equates to a 6% relative increase per year in rates of incident initiation (for a secular trend with an absolute increase of 2.5%) in the control group and a 24.3% relative increase in the intervention group. Subgroup analyses: For a subgroup of half our sample (e.g., stratifying by sex, age at visit, or race/ethnicity) we have 80% power to detect a difference in rates of 49% vs. 61%.</p>
                </sec>
                <sec id="Sec42">
                  <title>Implementation trial</title>
                  <p id="Par66"><italic>Quantitative analysis.</italic> Descriptive statistics (e.g., frequency, percentage mean, standard deviation [SD], median, range) will be used to summarize quantitative measures. Scores for Provider HPV Vaccine-related Knowledge/Practices will be modeled at the provider level using mixed models similarly to the methods for the Effectiveness Trial, to properly account for repeated observations and within-practice clustering, but with a continuous rather than binary outcome. Model-based predictions with confidence intervals will be reported over time and by intervention exposure, and will be displayed graphically. We expect to be underpowered for formal hypothesis testing, but model-based effect estimates for HPV-related Knowledge and Practices will be reported. <italic>Sample Size and Power.</italic> We recognize that we may not have sufficient power to test objective measures of provider HPV vaccine-related knowledge and practices, or objective ratings of the intervention; as such, the Implementation Trial is a secondary aim, and the provider knowledge/practices portion of the analysis will be exploratory.</p>
                  <p id="Par67"><italic>Qualitative analysis.</italic> We will code interview transcripts and analyze them using content analysis. Two investigators will evaluate each transcript using line-by-line open coding to develop a preliminary codebook of emerging themes. We will use the preliminary codebook to guide additional analyses, and will develop a robust codebook as additional transcripts are analyzed. We will use team discussions to arrive at a consensus regarding final coding, aggregate the codes, and categorize them to identify major themes. Data saturation will occur when no new themes emerge. Qualitative software (e.g., NVivo) will be used for analysis.</p>
                  <p id="Par68"><italic>Mixed methods: Integration of data</italic>. Results from the quantitative and qualitative analyses will be integrated through comparison to generate metainferences regarding the feasibility/acceptability of the intervention. The analysis will be weighted toward the qualitative strand [<xref ref-type="bibr" rid="CR54">54</xref>]. The mixed analysis will expand our understanding of providersâ€™ experiences implementing the intervention.</p>
                </sec>
              </sec>
              <sec id="Sec43">
                <title>Data management and safety monitoring plan</title>
                <p id="Par69">Participation in the research aspects (i.e., surveys and interviews) of this clinical trial are optional for healthcare providers. Intervention Champions will not have access to identifiable provider data and will not know which healthcare providers from their site choose to participate or not participate in the research aspects of the study. Nevertheless, it is possible that some healthcare providers who do not wish to participate in the research aspects of the study may perceive pressure to do so and may believe that not participating would be viewed negatively by their peers or superiors. Therefore, a data safety monitoring plan will be implemented to monitor for Unanticipated Problems related to research participation. The study PIs, and the Intervention Champions at each site, will be responsible for monitoring protocol conduct across all participating sites and reporting any deviations or unanticipated problems related to the protocol intervention and/or research procedures performed during this study to the study sIRB (UAB-IRB). Reports of unanticipated problems will include a description of the circumstances surrounding the unanticipated problem and the PI assessment of its impact on the studyâ€™s overall riskâ€“benefit ratio. If an unanticipated problem appears to significantly affect the studyâ€™s riskâ€“benefit ratio, an urgent review of the unanticipated problem will be made to determine whether immediate action is required. Based on the frequency and severity of unanticipated problems, the study PIs may deem it necessary to suspend or terminate the trial. When appropriate, the study PIs may recommend that unanticipated problems be reported to federal agencies.</p>
              </sec>
            </sec>
            <sec id="Sec44">
              <title>Discussion</title>
              <p id="Par70">The overall goal of this study is to prevent HPV-related neoplasms and their associated morbidity and mortality in the vulnerable population of young cancer survivors. We will test the effectiveness of HPV PROTECT â€“ an intervention aimed at improving HPV vaccination rates in young cancer survivors â€“ that is targeted to healthcare providers in the pediatric oncology setting. To our knowledge, this is the first evidence-based, provider-directed intervention to be adapted for pediatric oncology to specifically target the low uptake of the HPV vaccine among young cancer survivors.</p>
              <p id="Par71">Our intervention includes components that have been tested and proven effective in the general pediatric population (i.e., provider communication training [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], provider assessment feedback/coaching [<xref ref-type="bibr" rid="CR20">20</xref>â€“<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], and provider toolkit [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]). Additionally, in adapting the HPV PROTECT intervention for pediatric oncology, we have incorporated evidence specific to the young cancer survivor population, in order to address issues and concerns that are particularly relevant to these young survivors and to the healthcare providers caring for them (e.g., importance of recommendations from oncology providers, appropriate time to re-initiate vaccinations post-therapy, number of doses needed for series completion) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p>
              <p id="Par72">Our approach is innovative in several ways. We have established a consortium of participating institutions to test the HPV PROTECT intervention. These geographically-diverse institutions are representative of pediatric oncology practices of varying sizes and characteristics serving diverse and medically-underserved minority populations, and are especially enriched by sites serving populations in areas of lowest HPV vaccine uptake (i.e., U.S. southern states) [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Our investigative team brings together extensive clinical and research expertise (including expertise in implementation science), and our Intervention Champions at each site are well-engaged and immersed in their respective clinical programs and have ready-access to the populations of interest. Additionally, the hybrid clinical effectiveness-implementation trial design will allow us to determine the effectiveness of the provider-directed intervention, and to understand the mechanisms and processes underlying successful implementation of the intervention in the pediatric oncology setting. Finally, we will collect and evaluate data from multiple perspectives, including clinic-level objective vaccination rates, intervention fidelity measures, provider knowledge and practices relevant to HPV vaccination, and provider perspectives regarding intervention feasibility, acceptability, and appropriateness.</p>
              <p id="Par73">We also acknowledge some study limitations. We have addressed threats to internal validity of the study design through use of rigorous methodology that incorporates construction of cohorts inclusive of the entire targeted survivor population at each site. Nevertheless, it is possible that additional unmeasured effects, in addition to the intervention effect (e.g., a media campaign not related to the study) could affect vaccine uptake during the intervention and sustainability periods. Additionally, we recognize that it is possible that survivors who have clinic visits toward the end of each study year will have less time to receive their vaccinations. A sensitivity analysis will be conducted to address this issue. It is also possible that providers may not participate in the intervention activities, potentially affecting intervention fidelity. The Intervention Champions will track clinician engagement at their sites and provide coaching and additional opportunities for providers needing remediation. It is also possible that providers will consent to research participation but then fail to complete the required measures. To address this issue, study CRAs will monitor data collection in real-time and send reminders to participants who have not completed study measures, in order to optimize data collection.</p>
              <p id="Par74">Despite these limitations, this study addresses important gaps in knowledge relevant to the prevention of HPV-related malignancies in young cancer survivors. We will test the effectiveness of an evidence-based provider-directed intervention, adapted for the pediatric oncology setting, to increase HPV vaccine initiation in young cancer survivors receiving care in pediatric oncology clinics. We will also procure information regarding intervention delivery to inform future implementation efforts. If proven effective, HPV PROTECT will be readily disseminable for testing in the larger pediatric oncology community to increase HPV vaccine uptake in cancer survivors, facilitating protection against HPV-related morbidities for this vulnerable population.</p>
            </sec>
            <sec id="Sec45">
              <title>Trial status</title>
              <p id="Par75">UAB IRB Protocol Number: 300005305, initially approved 26 Jul 2020. Recruitment began 1 Feb 2021. Current protocol version: Amendment 2, 04/20/2022, approved 03 May 2022. Anticipated study completion date: 31 Jan 2026.</p>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>CAR</term>
                  <def>
                    <p id="Par5">Chimeric antigen receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>COVID-19</term>
                  <def>
                    <p id="Par6">Coronavirus disease of 2019</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CRA</term>
                  <def>
                    <p id="Par7">Clinical research assistant</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EMR</term>
                  <def>
                    <p id="Par8">Electronic medical record</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HIPAA</term>
                  <def>
                    <p id="Par9">Health information portability and accountability</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HPV</term>
                  <def>
                    <p id="Par10">Human papillomavirus</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IRB</term>
                  <def>
                    <p id="Par11">Institutional review board</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PCP</term>
                  <def>
                    <p id="Par12">Primary care provider</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PHI</term>
                  <def>
                    <p id="Par13">Personal health information</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PI</term>
                  <def>
                    <p id="Par14">Principal investigator</p>
                  </def>
                </def-item>
                <def-item>
                  <term>QI</term>
                  <def>
                    <p id="Par15">Quality improvement</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RE-AIM</term>
                  <def>
                    <p id="Par16">Reach, effectiveness, adoption, implementation, maintenance</p>
                  </def>
                </def-item>
                <def-item>
                  <term>REDCapÂ®</term>
                  <def>
                    <p id="Par17">Research Electronic Data Capture</p>
                  </def>
                </def-item>
                <def-item>
                  <term>sIRB</term>
                  <def>
                    <p id="Par18">Single institutional review board</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SMART</term>
                  <def>
                    <p id="Par19">Streamlined, multisite, accelerated resources for trials</p>
                  </def>
                </def-item>
                <def-item>
                  <term>Tdap</term>
                  <def>
                    <p id="Par20">Tetanus, diphtheria, and pertussis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>UAB</term>
                  <def>
                    <p id="Par21">University of Alabama at Birmingham</p>
                  </def>
                </def-item>
                <def-item>
                  <term>U.S.</term>
                  <def>
                    <p id="Par22">United States</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisherâ€™s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>Not applicable.</p>
              <sec id="FPar1">
                <title>Related articles</title>
                <p id="Par76">None.</p>
              </sec>
              <sec id="FPar2">
                <title>Model consent form/information sheet</title>
                <p id="Par77">Available from the study PIs upon request.</p>
              </sec>
              <sec id="FPar3">
                <title>Dissemination plan</title>
                <p id="Par78">Study results will be shared via conference proceedings and publications. Authors will include members of the study team; there is no plan for use of professional writers.</p>
              </sec>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authorsâ€™ contributions</title>
              <p>Conception and Design: WL, JLK, SB, JSR, MBG, GAC; Funding acquisition: WL, JLK; Methodology: WL, JLK, JSR, SB, MBG, GAC, VC, JA, SMC, MMG, SL, TBR, LMT, BC, PDCG; Writing â€“ original draft: WL, JLK, JSR, SB; Writing â€“ review and editing: WL, JLK, JSR, SB, BC, PDCG, VC, JA, SMC, MBG, GAC, MMG, SL, TBR, LMT. The authors read and approved the final manuscript.Â </p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This research is funded by a cooperative agreementÂ from the National Cancer Institute; <ext-link ext-link-type="uri" xlink:href="http://www.cancer.gov">www.cancer.gov</ext-link> (U01CA246567; PIs WL and JLK). The contents are solely the responsibility of the authors and do not represent official views of, nor endorsement, by the National Cancer Institute or other federal agencies. </p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>The study principal investigators, CRA at the site coordinating center, and statistician will have full access to the final data set. De-identified quantitative data underlying the published study results, with codebook, will be made available to researchers who provide a methodologically sound proposal to the study PIs, released under Creative Commons Attribution 4.0 Generic License (or equivalent), for up to 5Â years following study completion.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar5">
                <title>Ethics approval and consent to participate</title>
                <p id="Par79">The study described in this manuscript was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board (IRB-300005305), with UAB serving as the single IRB (sIRB) of record. In accordance with the SMART (Streamlined, Multisite, Accelerated Resources for Trials) IRB reliance model, participating sites ceded review to the UAB IRB as the Reviewing IRB under the Master Common Reciprocal IRB Authorization Agreement. Healthcare providers eligible for study participation receive an email from the study coordinating center with an information sheet, along with a link to an online survey. The IRB has authorized waiver of consent documentation; thus, completion of the survey implies consent. An item on the survey will ask the healthcare provider if they wish to participate in study interviews. Those indicating interest in interview participation are contacted by the study Clinical Research Assistant (CRA) at the study coordinating center via email or telephone. Verbal consent is obtained prior to interview initiation. There is no interaction between the study team and cancer survivors. Study involvement includes abstraction of existing clinical information only done by the site CRA under a HIPAA waiver as part of each siteâ€™s Quality Improvement initiative.</p>
              </notes>
              <notes id="FPar6">
                <title>Consent for publication</title>
                <p id="Par80">Not applicable.</p>
              </notes>
              <notes id="FPar7" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par81">The authors declare no competing interests.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ojha</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Jackson</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Tota</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Offutt-Powell</surname>
                      <given-names>TN</given-names>
                    </name>
                    <name>
                      <surname>Hudson</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Gurney</surname>
                      <given-names>JG</given-names>
                    </name>
                  </person-group>
                  <article-title>Younger age distribution of cervical cancer incidence among survivors of pediatric and young adult cancers</article-title>
                  <source>Gynecol Oncol</source>
                  <year>2014</year>
                  <volume>134</volume>
                  <issue>2</issue>
                  <fpage>309</fpage>
                  <lpage>313</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ygyno.2014.05.011</pub-id>
                  <?supplied-pmid 24875121?>
                  <pub-id pub-id-type="pmid">24875121</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ojha</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Tota</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Offutt-Powell</surname>
                      <given-names>TN</given-names>
                    </name>
                    <name>
                      <surname>Klosky</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Minniear</surname>
                      <given-names>TD</given-names>
                    </name>
                    <name>
                      <surname>Jackson</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Gurney</surname>
                      <given-names>JG</given-names>
                    </name>
                  </person-group>
                  <article-title>Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers</article-title>
                  <source>PLoS ONE</source>
                  <year>2013</year>
                  <volume>8</volume>
                  <issue>8</issue>
                  <fpage>e70349</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0070349</pub-id>
                  <?supplied-pmid 23940566?>
                  <pub-id pub-id-type="pmid">23940566</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bailey</surname>
                      <given-names>HH</given-names>
                    </name>
                    <name>
                      <surname>Chuang</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>duPont</surname>
                      <given-names>NC</given-names>
                    </name>
                    <name>
                      <surname>Eng</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Foxhall</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Merrill</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Wollins</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Blanke</surname>
                      <given-names>CD</given-names>
                    </name>
                  </person-group>
                  <article-title>American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention</article-title>
                  <source>J Clin Oncol</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <issue>15</issue>
                  <fpage>1803</fpage>
                  <lpage>1812</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2016.67.2014</pub-id>
                  <?supplied-pmid 27069078?>
                  <pub-id pub-id-type="pmid">27069078</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joura</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Giuliano</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Iversen</surname>
                      <given-names>OE</given-names>
                    </name>
                    <name>
                      <surname>Bouchard</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Mao</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Mehlsen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Moreira</surname>
                      <given-names>ED</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Ngan</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Petersen</surname>
                      <given-names>LK</given-names>
                    </name>
                    <name>
                      <surname>Lazcano-Ponce</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women</article-title>
                  <source>N Engl J Med</source>
                  <year>2015</year>
                  <volume>372</volume>
                  <issue>8</issue>
                  <fpage>711</fpage>
                  <lpage>723</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1405044</pub-id>
                  <?supplied-pmid 25693011?>
                  <pub-id pub-id-type="pmid">25693011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Castellsague</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Giuliano</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Goldstone</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Guevara</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mogensen</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Palefsky</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Group</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Shields</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Maansson</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Immunogenicity and safety of the 9-valent HPV vaccine in men</article-title>
                  <source>Vaccine</source>
                  <year>2015</year>
                  <volume>33</volume>
                  <issue>48</issue>
                  <fpage>6892</fpage>
                  <lpage>6901</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.088</pub-id>
                  <?supplied-pmid 26144901?>
                  <pub-id pub-id-type="pmid">26144901</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Klosky</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Hudson</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Connelly</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Wasilewski-Masker</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Francisco</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Gustafson</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Russell</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Sabbatini</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Human Papillomavirus Vaccination Rates in Young Cancer Survivors</article-title>
                  <source>J Clin Oncol</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <issue>31</issue>
                  <fpage>3582</fpage>
                  <lpage>3590</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2017.74.1843</pub-id>
                  <?supplied-pmid 28837404?>
                  <pub-id pub-id-type="pmid">28837404</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Landier</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Bhatia</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wong</surname>
                      <given-names>FL</given-names>
                    </name>
                    <name>
                      <surname>York</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Flynn</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Henneberg</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Adams</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Wasilewski-Masker</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Cherven</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial</article-title>
                  <source>Lancet Child Adolesc Health</source>
                  <year>2022</year>
                  <volume>6</volume>
                  <issue>1</issue>
                  <fpage>38</fpage>
                  <lpage>48</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2352-4642(21)00278-9</pub-id>
                  <?supplied-pmid 34767765?>
                  <pub-id pub-id-type="pmid">34767765</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carroll</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Massarelli</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Opzoomer</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Pekeles</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Pedneault</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Frappier</surname>
                      <given-names>JY</given-names>
                    </name>
                    <name>
                      <surname>Onetto</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Adolescents with chronic disease. Are they receiving comprehensive health care?</article-title>
                  <source>J Adolesc Health Care</source>
                  <year>1983</year>
                  <volume>4</volume>
                  <issue>4</issue>
                  <fpage>261</fpage>
                  <lpage>265</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0197-0070(83)80008-4</pub-id>
                  <?supplied-pmid 6643204?>
                  <pub-id pub-id-type="pmid">6643204</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Signorelli</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wakefield</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Fardell</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Wallace</surname>
                      <given-names>WHB</given-names>
                    </name>
                    <name>
                      <surname>Robertson</surname>
                      <given-names>EG</given-names>
                    </name>
                    <name>
                      <surname>McLoone</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Cohn</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The impact of long-term follow-up care for childhood cancer survivors: A systematic review</article-title>
                  <source>Crit Rev Oncol Hematol</source>
                  <year>2017</year>
                  <volume>114</volume>
                  <fpage>131</fpage>
                  <lpage>138</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.critrevonc.2017.04.007</pub-id>
                  <?supplied-pmid 28477741?>
                  <pub-id pub-id-type="pmid">28477741</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Melmed</surname>
                      <given-names>GY</given-names>
                    </name>
                    <name>
                      <surname>Ippoliti</surname>
                      <given-names>AF</given-names>
                    </name>
                    <name>
                      <surname>Papadakis</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Tran</surname>
                      <given-names>TT</given-names>
                    </name>
                    <name>
                      <surname>Birt</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Frenck</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Targan</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Vasiliauskas</surname>
                      <given-names>EA</given-names>
                    </name>
                  </person-group>
                  <article-title>Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses</article-title>
                  <source>Am J Gastroenterol</source>
                  <year>2006</year>
                  <volume>101</volume>
                  <issue>8</issue>
                  <fpage>1834</fpage>
                  <lpage>1840</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1572-0241.2006.00646.x</pub-id>
                  <?supplied-pmid 16817843?>
                  <pub-id pub-id-type="pmid">16817843</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Committee</surname>
                      <given-names>NVA</given-names>
                    </name>
                  </person-group>
                  <article-title>Overcoming Barriers to Low HPV Vaccine Uptake in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015</article-title>
                  <source>Public Health Rep</source>
                  <year>2016</year>
                  <volume>131</volume>
                  <issue>1</issue>
                  <fpage>17</fpage>
                  <lpage>25</lpage>
                  <pub-id pub-id-type="doi">10.1177/003335491613100106</pub-id>
                  <pub-id pub-id-type="pmid">26843665</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hofstetter</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Lappetito</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Stockwell</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Rosenthal</surname>
                      <given-names>SL</given-names>
                    </name>
                  </person-group>
                  <article-title>Human Papillomavirus Vaccination of Adolescents with Chronic Medical Conditions: A National Survey of Pediatric Subspecialists</article-title>
                  <source>J Pediatr Adolesc Gynecol</source>
                  <year>2017</year>
                  <volume>30</volume>
                  <issue>1</issue>
                  <fpage>88</fpage>
                  <lpage>95</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jpag.2016.08.005</pub-id>
                  <?supplied-pmid 27542999?>
                  <pub-id pub-id-type="pmid">27542999</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Crawford</surname>
                      <given-names>NW</given-names>
                    </name>
                    <name>
                      <surname>Bines</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Royle</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Buttery</surname>
                      <given-names>JP</given-names>
                    </name>
                  </person-group>
                  <article-title>Optimizing immunization in pediatric special risk groups</article-title>
                  <source>Expert Rev Vaccines</source>
                  <year>2011</year>
                  <volume>10</volume>
                  <issue>2</issue>
                  <fpage>175</fpage>
                  <lpage>186</lpage>
                  <pub-id pub-id-type="doi">10.1586/erv.10.157</pub-id>
                  <?supplied-pmid 21332267?>
                  <pub-id pub-id-type="pmid">21332267</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <mixed-citation publication-type="other">Care for childhood cancer survivors. National Cancer Institute, Rockville, MD, USA. Reviewed 28 Sept 2021 [cited 26 May 2022]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-cancer/coping/survivorship/child-care">https://www.cancer.gov/about-cancer/coping/survivorship/child-care</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fu</surname>
                      <given-names>LY</given-names>
                    </name>
                    <name>
                      <surname>Bonhomme</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Cooper</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Joseph</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Zimet</surname>
                      <given-names>GD</given-names>
                    </name>
                  </person-group>
                  <article-title>Educational interventions to increase HPV vaccination acceptance: a systematic review</article-title>
                  <source>Vaccine</source>
                  <year>2014</year>
                  <volume>32</volume>
                  <issue>17</issue>
                  <fpage>1901</fpage>
                  <lpage>1920</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.091</pub-id>
                  <?supplied-pmid 24530401?>
                  <pub-id pub-id-type="pmid">24530401</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <mixed-citation publication-type="other">HPVIQ. University of North Carolina, Gillings School of Public Health, Chapel Hill, NC, USA. Reviewed 2022 [cited 26 May 2022]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.hpviq.org/">https://www.hpviq.org/</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Malo</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Quinn</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Lathren</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial</article-title>
                  <source>Pediatrics</source>
                  <year>2017</year>
                  <volume>139</volume>
                  <issue>1</issue>
                  <fpage>e20161764</fpage>
                  <pub-id pub-id-type="doi">10.1542/peds.2016-1764</pub-id>
                  <?supplied-pmid 27940512?>
                  <pub-id pub-id-type="pmid">27940512</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dempsey</surname>
                      <given-names>AF</given-names>
                    </name>
                    <name>
                      <surname>Pyrznawoski</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lockhart</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Barnard</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Campagna</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Garrett</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Fisher</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Dickinson</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>O'Leary</surname>
                      <given-names>ST</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of a Health Care Professional Communication Training Intervention on Adolescent Human Papillomavirus Vaccination: A Cluster Randomized Clinical Trial</article-title>
                  <source>JAMA Pediatr</source>
                  <year>2018</year>
                  <volume>172</volume>
                  <issue>5</issue>
                  <fpage>e180016</fpage>
                  <pub-id pub-id-type="doi">10.1001/jamapediatrics.2018.0016</pub-id>
                  <?supplied-pmid 29507952?>
                  <pub-id pub-id-type="pmid">29507952</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Calo</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Moss</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Marciniak</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                  </person-group>
                  <article-title>Provider communication and HPV vaccination: The impact of recommendation quality</article-title>
                  <source>Vaccine</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <issue>9</issue>
                  <fpage>1187</fpage>
                  <lpage>1192</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.023</pub-id>
                  <?supplied-pmid 26812078?>
                  <pub-id pub-id-type="pmid">26812078</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Dayton</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Moss</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Sparks</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Grimshaw</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Bowling</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                  </person-group>
                  <article-title>Increasing provision of adolescent vaccines in primary care: a randomized controlled trial</article-title>
                  <source>Pediatrics</source>
                  <year>2014</year>
                  <volume>134</volume>
                  <issue>2</issue>
                  <fpage>e346</fpage>
                  <lpage>353</lpage>
                  <pub-id pub-id-type="doi">10.1542/peds.2013-4257</pub-id>
                  <?supplied-pmid 25002671?>
                  <pub-id pub-id-type="pmid">25002671</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Perkins</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Zisblatt</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Legler</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Trucks</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Hanchate</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gorin</surname>
                      <given-names>SS</given-names>
                    </name>
                  </person-group>
                  <article-title>Effectiveness of a provider-focused intervention to improve HPV vaccination rates in boys and girls</article-title>
                  <source>Vaccine</source>
                  <year>2015</year>
                  <volume>33</volume>
                  <issue>9</issue>
                  <fpage>1223</fpage>
                  <lpage>1229</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.vaccine.2014.11.021</pub-id>
                  <?supplied-pmid 25448095?>
                  <pub-id pub-id-type="pmid">25448095</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rand</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Schaffer</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Dhepyasuwan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Blumkin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Albertin</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Serwint</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Darden</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Humiston</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Stratbucker</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Provider Communication, Prompts, and Feedback to Improve HPV Vaccination Rates in Resident Clinics</article-title>
                  <source>Pediatrics</source>
                  <year>2018</year>
                  <volume>141</volume>
                  <issue>4</issue>
                  <fpage>e20170498</fpage>
                  <pub-id pub-id-type="doi">10.1542/peds.2017-0498</pub-id>
                  <?supplied-pmid 29540572?>
                  <pub-id pub-id-type="pmid">29540572</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Calo</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Leeman</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Heisler-MacKinnon</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Averette</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Sanchez</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kornides</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                  </person-group>
                  <article-title>Coaching primary care clinics for HPV vaccination quality improvement: Comparing in-person and webinar implementation</article-title>
                  <source>Transl Behav Med</source>
                  <year>2019</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <fpage>23</fpage>
                  <lpage>31</lpage>
                  <pub-id pub-id-type="doi">10.1093/tbm/iby008</pub-id>
                  <?supplied-pmid 29471460?>
                  <pub-id pub-id-type="pmid">29471460</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Moss</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Dayton</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Grimshaw</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparing in-person and webinar delivery of an immunization quality improvement program: a process evaluation of the adolescent AFIX trial</article-title>
                  <source>Implement Sci</source>
                  <year>2014</year>
                  <volume>9</volume>
                  <fpage>21</fpage>
                  <pub-id pub-id-type="doi">10.1186/1748-5908-9-21</pub-id>
                  <?supplied-pmid 24533515?>
                  <pub-id pub-id-type="pmid">24533515</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zimet</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Dixon</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Xiao</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tu</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Kulkarni</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Dugan</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sheley</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Downs</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Simple and Elaborated Clinician Reminder Prompts for Human Papillomavirus Vaccination: A Randomized Clinical Trial</article-title>
                  <source>Acad Pediatr</source>
                  <year>2018</year>
                  <volume>18</volume>
                  <issue>2S</issue>
                  <fpage>S66</fpage>
                  <lpage>S71</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.acap.2017.11.002</pub-id>
                  <?supplied-pmid 29502640?>
                  <pub-id pub-id-type="pmid">29502640</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Szilagyi</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Serwint</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Humiston</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Rand</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Schaffer</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vincelli</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Dhepyasuwan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Blumkin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Albertin</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Curtis</surname>
                      <given-names>CR</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of provider prompts on adolescent immunization rates: a randomized trial</article-title>
                  <source>Acad Pediatr</source>
                  <year>2015</year>
                  <volume>15</volume>
                  <issue>2</issue>
                  <fpage>149</fpage>
                  <lpage>157</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.acap.2014.10.006</pub-id>
                  <?supplied-pmid 25748976?>
                  <pub-id pub-id-type="pmid">25748976</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kornides</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Calo</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Heisler-MacKinnon</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                  </person-group>
                  <article-title>U.S. Primary Care Clinics' Experiences During Introduction of the 9-Valent HPV Vaccine</article-title>
                  <source>J Community Health</source>
                  <year>2018</year>
                  <volume>43</volume>
                  <issue>2</issue>
                  <fpage>291</fpage>
                  <lpage>296</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10900-017-0420-x</pub-id>
                  <?supplied-pmid 28856551?>
                  <pub-id pub-id-type="pmid">28856551</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Malo</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                  </person-group>
                  <article-title>Messages to Motivate Human Papillomavirus Vaccination: National Studies of Parents and Physicians</article-title>
                  <source>Cancer Epidemiol Biomarkers Prev</source>
                  <year>2016</year>
                  <volume>25</volume>
                  <issue>10</issue>
                  <fpage>1383</fpage>
                  <lpage>1391</lpage>
                  <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0224</pub-id>
                  <?supplied-pmid 27694109?>
                  <pub-id pub-id-type="pmid">27694109</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moss</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Reiter</surname>
                      <given-names>PL</given-names>
                    </name>
                    <name>
                      <surname>Rimer</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                  </person-group>
                  <article-title>Collaborative patient-provider communication and uptake of adolescent vaccines</article-title>
                  <source>Soc Sci Med</source>
                  <year>2016</year>
                  <volume>159</volume>
                  <fpage>100</fpage>
                  <lpage>107</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.socscimed.2016.04.030</pub-id>
                  <?supplied-pmid 27176467?>
                  <pub-id pub-id-type="pmid">27176467</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Malo</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                    <name>
                      <surname>Lathren</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                  </person-group>
                  <article-title>Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation</article-title>
                  <source>Implement Sci</source>
                  <year>2018</year>
                  <volume>13</volume>
                  <issue>1</issue>
                  <fpage>57</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13012-018-0743-8</pub-id>
                  <?supplied-pmid 29673374?>
                  <pub-id pub-id-type="pmid">29673374</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Parks</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Margolis</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>McRee</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Terk</surname>
                      <given-names>JV</given-names>
                    </name>
                  </person-group>
                  <article-title>Implementing Evidence-Based Strategies to Improve HPV Vaccine Delivery</article-title>
                  <source>Pediatrics</source>
                  <year>2019</year>
                  <volume>144</volume>
                  <issue>1</issue>
                  <fpage>e20182500</fpage>
                  <pub-id pub-id-type="doi">10.1542/peds.2018-2500</pub-id>
                  <?supplied-pmid 31209158?>
                  <pub-id pub-id-type="pmid">31209158</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gilkey</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Malo</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>NT</given-names>
                    </name>
                  </person-group>
                  <article-title>Quality of physician communication about human papillomavirus vaccine: findings from a national survey</article-title>
                  <source>Cancer Epidemiol Biomarkers Prev</source>
                  <year>2015</year>
                  <volume>24</volume>
                  <issue>11</issue>
                  <fpage>1673</fpage>
                  <lpage>1679</lpage>
                  <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-15-0326</pub-id>
                  <?supplied-pmid 26494764?>
                  <pub-id pub-id-type="pmid">26494764</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <mixed-citation publication-type="other">About immunization information systems. Centers for Disease Control and Prevention, Atlanta, GA, USA. Reviewed 7 Jun 2019 [cited 26 May 2022]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/vaccines/programs/iis/about.html">http://www.cdc.gov/vaccines/programs/iis/about.html</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <mixed-citation publication-type="other">Oliver K, McCorkell C, Pister I, Majid N, Benkel DH, Zucker JR: Improving HPV vaccine delivery at school-based health centers. Hum Vaccin Immunother. 2019;15(7-8):1870â€“7.</mixed-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dombkowski</surname>
                      <given-names>KJ</given-names>
                    </name>
                    <name>
                      <surname>Harrington</surname>
                      <given-names>LB</given-names>
                    </name>
                    <name>
                      <surname>Dong</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Seasonal influenza vaccination reminders for children with high-risk conditions: a registry-based randomized trial</article-title>
                  <source>Am J Prev Med</source>
                  <year>2012</year>
                  <volume>42</volume>
                  <issue>1</issue>
                  <fpage>71</fpage>
                  <lpage>75</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.amepre.2011.09.028</pub-id>
                  <?supplied-pmid 22176850?>
                  <pub-id pub-id-type="pmid">22176850</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Suh</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Saville</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Daley</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Glazner</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Barrow</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Stokley</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dong</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Beaty</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Dickinson</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Kempe</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Effectiveness and net cost of reminder/recall for adolescent immunizations</article-title>
                  <source>Pediatrics</source>
                  <year>2012</year>
                  <volume>129</volume>
                  <issue>6</issue>
                  <fpage>e1437</fpage>
                  <lpage>1445</lpage>
                  <pub-id pub-id-type="doi">10.1542/peds.2011-1714</pub-id>
                  <?supplied-pmid 22566415?>
                  <pub-id pub-id-type="pmid">22566415</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kempe</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Saville</surname>
                      <given-names>AW</given-names>
                    </name>
                    <name>
                      <surname>Dickinson</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Beaty</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Eisert</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gurfinkel</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Brewer</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Shull</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Herrero</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Herlihy</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Collaborative centralized reminder/recall notification to increase immunization rates among young children: a comparative effectiveness trial</article-title>
                  <source>JAMA Pediatr</source>
                  <year>2015</year>
                  <volume>169</volume>
                  <issue>4</issue>
                  <fpage>365</fpage>
                  <lpage>373</lpage>
                  <pub-id pub-id-type="doi">10.1001/jamapediatrics.2014.3670</pub-id>
                  <?supplied-pmid 25706340?>
                  <pub-id pub-id-type="pmid">25706340</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fuller</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Walter</surname>
                      <given-names>EB</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Dole</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>O'Hara</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Herring</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Durkin</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Specker</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Wey</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>State-Level Immunization Information Systems: Potential for Childhood Immunization Data Linkages</article-title>
                  <source>Matern Child Health J</source>
                  <year>2017</year>
                  <volume>21</volume>
                  <issue>1</issue>
                  <fpage>29</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10995-016-2090-1</pub-id>
                  <?supplied-pmid 27443650?>
                  <pub-id pub-id-type="pmid">27443650</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murthy</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Rodgers</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Pabst</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Fiebelkorn</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Ng</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Progress in Childhood Vaccination Data in Immunization Information Systems - United States, 2013â€“2016</article-title>
                  <source>MMWR Morb Mortal Wkly Rep</source>
                  <year>2017</year>
                  <volume>66</volume>
                  <issue>43</issue>
                  <fpage>1178</fpage>
                  <lpage>1181</lpage>
                  <pub-id pub-id-type="doi">10.15585/mmwr.mm6643a4</pub-id>
                  <?supplied-pmid 29095809?>
                  <pub-id pub-id-type="pmid">29095809</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Castellino</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Pleasant</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Keyes</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Poehling</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Tooze</surname>
                      <given-names>JA</given-names>
                    </name>
                  </person-group>
                  <article-title>Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer</article-title>
                  <source>J Cancer Surviv</source>
                  <year>2019</year>
                  <volume>13</volume>
                  <issue>5</issue>
                  <fpage>730</fpage>
                  <lpage>738</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11764-019-00791-9</pub-id>
                  <?supplied-pmid 31342304?>
                  <pub-id pub-id-type="pmid">31342304</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Curran</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Bauer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mittman</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Pyne</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Stetler</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact</article-title>
                  <source>Med Care</source>
                  <year>2012</year>
                  <volume>50</volume>
                  <issue>3</issue>
                  <fpage>217</fpage>
                  <lpage>226</lpage>
                  <pub-id pub-id-type="doi">10.1097/MLR.0b013e3182408812</pub-id>
                  <?supplied-pmid 22310560?>
                  <pub-id pub-id-type="pmid">22310560</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Landes</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>McBain</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Curran</surname>
                      <given-names>GM</given-names>
                    </name>
                  </person-group>
                  <article-title>An introduction to effectiveness-implementation hybrid designs</article-title>
                  <source>Psychiatry Res</source>
                  <year>2019</year>
                  <volume>280</volume>
                  <fpage>112513</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.psychres.2019.112513</pub-id>
                  <?supplied-pmid 31434011?>
                  <pub-id pub-id-type="pmid">31434011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hemming</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Haines</surname>
                      <given-names>TP</given-names>
                    </name>
                    <name>
                      <surname>Chilton</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Girling</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Lilford</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting</article-title>
                  <source>BMJ</source>
                  <year>2015</year>
                  <volume>350</volume>
                  <fpage>h391</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.h391</pub-id>
                  <?supplied-pmid 25662947?>
                  <pub-id pub-id-type="pmid">25662947</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petrosky</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bocchini</surname>
                      <given-names>JA</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Hariri</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chesson</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Curtis</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Saraiya</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Unger</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Markowitz</surname>
                      <given-names>LE</given-names>
                    </name>
                  </person-group>
                  <article-title>Centers for Disease C, Prevention: Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices</article-title>
                  <source>MMWR Morb Mortal Wkly Rep</source>
                  <year>2015</year>
                  <volume>64</volume>
                  <issue>11</issue>
                  <fpage>300</fpage>
                  <lpage>304</lpage>
                  <?supplied-pmid 25811679?>
                  <pub-id pub-id-type="pmid">25811679</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cesaro</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Giacchino</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Fioredda</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Barone</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Battisti</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Bezzio</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Frenos</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>De Santis</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Livadiotti</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Marinello</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Guidelines on vaccinations in paediatric haematology and oncology patients</article-title>
                  <source>Biomed Res Int</source>
                  <year>2014</year>
                  <volume>2014</volume>
                  <fpage>707691</fpage>
                  <pub-id pub-id-type="doi">10.1155/2014/707691</pub-id>
                  <?supplied-pmid 24868544?>
                  <pub-id pub-id-type="pmid">24868544</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Glasgow</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Vogt</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Boles</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Evaluating the public health impact of health promotion interventions: the RE-AIM framework</article-title>
                  <source>Am J Public Health</source>
                  <year>1999</year>
                  <volume>89</volume>
                  <issue>9</issue>
                  <fpage>1322</fpage>
                  <lpage>1327</lpage>
                  <pub-id pub-id-type="doi">10.2105/AJPH.89.9.1322</pub-id>
                  <?supplied-pmid 10474547?>
                  <pub-id pub-id-type="pmid">10474547</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kessler</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Purcell</surname>
                      <given-names>EP</given-names>
                    </name>
                    <name>
                      <surname>Glasgow</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Klesges</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Benkeser</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Peek</surname>
                      <given-names>CJ</given-names>
                    </name>
                  </person-group>
                  <article-title>What does it mean to "employ" the RE-AIM model?</article-title>
                  <source>Eval Health Prof</source>
                  <year>2013</year>
                  <volume>36</volume>
                  <issue>1</issue>
                  <fpage>44</fpage>
                  <lpage>66</lpage>
                  <pub-id pub-id-type="doi">10.1177/0163278712446066</pub-id>
                  <?supplied-pmid 22615498?>
                  <pub-id pub-id-type="pmid">22615498</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gerke</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lewis</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Prusaczyk</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hanley</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Baumann</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Proctor</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <source>Implementation outcomes</source>
                  <year>2017</year>
                  <publisher-loc>St. Louis</publisher-loc>
                  <publisher-name>Washington University</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hirth</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature</article-title>
                  <source>Hum Vaccin Immunother</source>
                  <year>2019</year>
                  <volume>15</volume>
                  <issue>1</issue>
                  <fpage>146</fpage>
                  <lpage>155</lpage>
                  <pub-id pub-id-type="doi">10.1080/21645515.2018.1512453</pub-id>
                  <?supplied-pmid 30148974?>
                  <pub-id pub-id-type="pmid">30148974</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rahman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Islam</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Berenson</surname>
                      <given-names>AB</given-names>
                    </name>
                  </person-group>
                  <article-title>Differences in HPV Immunization Levels Among Young Adults in Various Regions of the United States</article-title>
                  <source>J Community Health</source>
                  <year>2015</year>
                  <volume>40</volume>
                  <issue>3</issue>
                  <fpage>404</fpage>
                  <lpage>408</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10900-015-9995-2</pub-id>
                  <?supplied-pmid 25669443?>
                  <pub-id pub-id-type="pmid">25669443</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harris</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Thielke</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Payne</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Conde</surname>
                      <given-names>JG</given-names>
                    </name>
                  </person-group>
                  <article-title>Research electronic data capture (REDCap)â€“a metadata-driven methodology and workflow process for providing translational research informatics support</article-title>
                  <source>J Biomed Inform</source>
                  <year>2009</year>
                  <volume>42</volume>
                  <issue>2</issue>
                  <fpage>377</fpage>
                  <lpage>381</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jbi.2008.08.010</pub-id>
                  <?supplied-pmid 18929686?>
                  <pub-id pub-id-type="pmid">18929686</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wodi</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Murthy</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Bernstein</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>McNally</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Cineas</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ault</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022</article-title>
                  <source>MMWR Morb Mortal Wkly Rep</source>
                  <year>2022</year>
                  <volume>71</volume>
                  <issue>7</issue>
                  <fpage>234</fpage>
                  <lpage>237</lpage>
                  <pub-id pub-id-type="doi">10.15585/mmwr.mm7107a2</pub-id>
                  <?supplied-pmid 35176011?>
                  <pub-id pub-id-type="pmid">35176011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walker</surname>
                      <given-names>TY</given-names>
                    </name>
                    <name>
                      <surname>Elam-Evans</surname>
                      <given-names>LD</given-names>
                    </name>
                    <name>
                      <surname>Singleton</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Yankey</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Markowitz</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Fredua</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Meyer</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Stokley</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13â€“17 Years - United States, 2016</article-title>
                  <source>MMWR Morb Mortal Wkly Rep</source>
                  <year>2017</year>
                  <volume>66</volume>
                  <issue>33</issue>
                  <fpage>874</fpage>
                  <lpage>882</lpage>
                  <pub-id pub-id-type="doi">10.15585/mmwr.mm6633a2</pub-id>
                  <?supplied-pmid 28837546?>
                  <pub-id pub-id-type="pmid">28837546</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cresswell</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Plano Clark</surname>
                      <given-names>VL</given-names>
                    </name>
                  </person-group>
                  <source>Designing and Conducting Mixed Methods Research</source>
                  <year>2010</year>
                  <edition>2</edition>
                  <publisher-loc>Thousand Oaks, CA</publisher-loc>
                  <publisher-name>Sage</publisher-name>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
